AMS:LSE-Advanced Medical Solutions Group plc (GBX)

COMMON STOCK | Medical Instruments & Supplies | LSE

Last Closing Price

GBX 277.00

Change

-3.50 (-1.25)%

Market Cap

GBX 0.60B

Volume

0.14M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Advanced Medical Solutions Group plc, together with its subsidiaries, designs, develops, manufactures, and distributes products for the wound care, surgical, and wound closure markets in the United Kingdom, Germany, Europe, the United States, and internationally. It operates in two segments, Surgical and Woundcare. The Surgical segment offers topical tissue adhesives for wound closure and sealing under the LiquiBand; sutures and collagen based products for the surgical and dental markets under the RESORBA; collagens; and laparoscopic device which reduces surgical complications under the LiquiBand Fix8 brands. The Woundcare segment provides wound care platform technologies, which include alginates, foams, films, fibres, hydrogels, antimicrobial dressings, and hydrocolloids, as well as wound care products under the ActivHeal. It also sells its products under the Seal-G and Biomatlante brand names, such as Moldable Bone Graft Substitute, a biphasic calcium phosphate synthetic bone graft substitute that includes Syringes, Inserts, and In'Oss; EZ Cure, a collagen membranes; and Osteotwin, a Biocompatible Interference Resorbable Screw. The company was founded in 1991 and is headquartered in Winsford, the United Kingdom. Address: Premier Park, Winsford, United Kingdom, CW7 3RT

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-05-10 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
CTEC:LSE ConvaTec Group Plc

-4.30 (-1.85%)

GBX4.65B 58.00 12.79
BVC:LSE BATM Advanced Communications L..

-4.40 (-4.66%)

GBX0.42B 59.00 19.62
TSTL:LSE Tristel plc

-5.00 (-0.87%)

GBX0.27B 51.34 27.18
ODX:LSE Omega Diagnostics Group PLC

-6.50 (-7.74%)

GBX0.15B 16.43 106.33

ETFs Containing AMS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Instruments & Supplies)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 13.99% 60% D- 66% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 13.99% 60% D- 60% D-
Trailing 12 Months  
Capital Gain 15.18% 80% B- 30% F
Dividend Return 0.64% 33% F 14% F
Total Return 15.82% 80% B- 29% F
Trailing 5 Years  
Capital Gain 52.83% 25% F 60% D-
Dividend Return 3.28% 50% F 10% F
Total Return 56.10% 25% F 58% F
Average Annual (5 Year Horizon)  
Capital Gain 4.41% 40% F 45% F
Dividend Return 0.45% 33% F 27% F
Total Return 4.86% 40% F 43% F
Risk Return Profile  
Volatility (Standard Deviation) 25.48% 100% A+ 44% F
Risk Adjusted Return 19.07% 40% F 43% F
Market Capitalization 0.60B 80% B- 70% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Instruments & Supplies)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 71.92 20% F 13% F
Price/Book Ratio 3.11 100% A+ 31% F
Price / Cash Flow Ratio 28.11 60% D- 18% F
EV/EBITDA 33.88 40% F 17% F
Management Effectiveness  
Return on Equity 4.36% 40% F 62% D-
Return on Invested Capital 5.10% 40% F 62% D-
Return on Assets 3.11% 40% F 68% D+
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.71 60% D- 74% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector